• Pharmacology
  • Allergy, Immunology, and ENT
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious Diseases
  • Neurology
  • OB/GYN
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Mental, Behavioral and Development Health
  • Oncology
  • Rheumatology
  • Sexual Health
  • Pain

Update black box warnings on antidepressants, says FDA

Article

The Food and Drug Administration proposed that all manufacturers of antidepressant meds update their existing black box warnings. The product labels should include warnings about increased risks of suicidal thinking and behavior, in 18- to 24-year olds, usually in the first two months of treatment [more].

The Food and Drug Administration proposed that all manufacturers of antidepressant meds update their existing black box warnings. The product labels should include warnings about increased risks of suicidal thinking and behavior, in 18- to 24-year olds, usually in the first two months of treatment [more].

The proposed labeling changes also include language stating that scientific data did not show this increased risk in adults older than 24, and that adults ages 65 and older taking antidepressants have a decreased risk of suicide.

The proposed change applies to the entire category of antidepressants, and follows similar labeling changes made in 2005 that warned of a suicide risk in children and adolescents who take antidepressants.

Related Videos
Natasha Hoyte, MPH, CPNP-PC
Lauren Flagg
Venous thromboembolism, Heparin-induced thrombocytopenia, and direct oral anticoagulants | Image credit: Contemporary Pediatrics
Jessica Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
Sally Humphrey, DNP, APRN, CPNP-PC | Image Credit: Contemporary Pediatrics
Ashley Gyura, DNP, CPNP-PC | Image Credit: Children's Minnesota
Congenital heart disease and associated genetic red flags
Traci Gonzales, MSN, APRN, CPNP-PC
© 2024 MJH Life Sciences

All rights reserved.